Trials / Active Not Recruiting
Active Not RecruitingNCT05118776
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC40 tablets | ASC40 tablets administered orally once daily |
| DRUG | Placebo tablets | Placebo administered orally once daily. |
| DRUG | Bevacizumab | Bevacizumab once every 2 weeks, intravenous drip. |
Timeline
- Start date
- 2022-01-21
- Primary completion
- 2025-06-01
- Completion
- 2025-06-01
- First posted
- 2021-11-12
- Last updated
- 2024-10-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05118776. Inclusion in this directory is not an endorsement.